SLC5A2 and hydrops fetalis: The primary endpoint was the composite of cardiovascular death or HF hospitalization.<h4>Results</h4>Treatment with SGLT2 inhibitors reduced the risk of the primary endpoint by 22% in the strict group (HR: 0.78, 95% CI: 0.60-1.03, with a confidence interval that includes the null) and by 27% in the broad group (HR: 0.73, 95% CI: 0.59-0.90).